| pubmed-article:15233548 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15233548 | lifeskim:mentions | umls-concept:C0221908 | lld:lifeskim |
| pubmed-article:15233548 | lifeskim:mentions | umls-concept:C0040132 | lld:lifeskim |
| pubmed-article:15233548 | lifeskim:mentions | umls-concept:C0007097 | lld:lifeskim |
| pubmed-article:15233548 | lifeskim:mentions | umls-concept:C0439682 | lld:lifeskim |
| pubmed-article:15233548 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:15233548 | lifeskim:mentions | umls-concept:C0245382 | lld:lifeskim |
| pubmed-article:15233548 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15233548 | pubmed:dateCreated | 2004-7-5 | lld:pubmed |
| pubmed-article:15233548 | pubmed:abstractText | Preoperative follicular lesion characterisation represents an unsolved diagnostic problem in thyroid nodular disease. Although fine-needle aspiration biopsy is the most reliable preoperative diagnostic procedure, it shows inherent limitations in differentiating adenoma from follicular carcinoma and, sometimes, follicular variants of papillary carcinoma. Galectin-3 cytoplasmic neoexpression has been proposed as a peculiar feature of thyroid malignant cells, easily detectable in cytological and histological samples. The aim of this study was to re-evaluate the galectin-3 expression in a large sample of thyroid lesions using an immunohistocytochemical biotin-free detection system and a specific anti-human-galectin-3 monoclonal antibody in order to avoid the interference of technical factors, a cause of conflicting results recently reported by some authors. We analysed galectin-3 expression of 39 follicular carcinomas, 26 papillary carcinomas, and 105 adenomas in both cell-block samples and their histological counterparts. All cell-block and histological papillary carcinoma samples showed high levels of galectin-3 immunoreactivity. Thirty-four follicular carcinomas were positive, whereas 5 were negative in cell-blocks but positive in their histological counterparts. Twelve out of 105 adenomas expressed galectin-3 in cell-blocks and histological samples. The diagnostic accuracy of preoperative galectin-3 evaluation in adenomas vs follicular carcinomas was 90.0%. Galectin-3 expression was also investigated in 22 minimally-invasive follicular carcinomas. All of them showed galectin-3 immunoreactivity in both cytological and histological specimens with the exception of two cases, where galectin-3 positivity was observed only in the surgical material. The routine correct use of galectin-3, by increasing the diagnostic accuracy of conventional cytology, improves the management of thyroid nodules and can lead to a sensitive reduction of useless thyroid surgeries. | lld:pubmed |
| pubmed-article:15233548 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15233548 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15233548 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15233548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15233548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15233548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15233548 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15233548 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15233548 | pubmed:issn | 0391-4097 | lld:pubmed |
| pubmed-article:15233548 | pubmed:author | pubmed-author:ConticelloSS | lld:pubmed |
| pubmed-article:15233548 | pubmed:author | pubmed-author:OrlandiFF | lld:pubmed |
| pubmed-article:15233548 | pubmed:author | pubmed-author:MussaAA | lld:pubmed |
| pubmed-article:15233548 | pubmed:author | pubmed-author:AversaSS | lld:pubmed |
| pubmed-article:15233548 | pubmed:author | pubmed-author:PapottiMM | lld:pubmed |
| pubmed-article:15233548 | pubmed:author | pubmed-author:PulighedduBB | lld:pubmed |
| pubmed-article:15233548 | pubmed:author | pubmed-author:CappiaSS | lld:pubmed |
| pubmed-article:15233548 | pubmed:author | pubmed-author:SaggioratoEE | lld:pubmed |
| pubmed-article:15233548 | pubmed:author | pubmed-author:DeandreisDD | lld:pubmed |
| pubmed-article:15233548 | pubmed:author | pubmed-author:AreccoFF | lld:pubmed |
| pubmed-article:15233548 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15233548 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:15233548 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15233548 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15233548 | pubmed:pagination | 311-7 | lld:pubmed |
| pubmed-article:15233548 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:meshHeading | pubmed-meshheading:15233548... | lld:pubmed |
| pubmed-article:15233548 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15233548 | pubmed:articleTitle | Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. | lld:pubmed |
| pubmed-article:15233548 | pubmed:affiliation | Section of Endocrinology, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. enrico.saggiorato@unito.it | lld:pubmed |
| pubmed-article:15233548 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15233548 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15233548 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15233548 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15233548 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15233548 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15233548 | lld:pubmed |
